Voices
FDA Approves Enhertu for Two Indications in HER2-Positive Early-Stage Breast Cancer – The Babak Lab
The Babak Lab/LinkedIn

FDA Approves Enhertu for Two Indications in HER2-Positive Early-Stage Breast Cancer – The Babak Lab

The Babak Lab shared a post on X:

“The US FDA has approved fam-trastuzumab deruxtecan-nxki (Enhertu, T-DXd) for two separate indications in HER2-positive early-stage breast cancer, further expanding the role of antibody-drug conjugates in earlier treatment settings.”

FDA approves two separate indications for fam-trastuzumab deruxtecan-nxki in HER2-positive early-stage breast cancer

The Babak Lab

Other articles about The Babak Lab on OncoDaily.

Breast Cancer cancer Enhertu fam-trastuzumab deruxtecan-nxki HER2-positive OncoDaily Oncology T-Dxd The Babak Lab US FDA